Fidelity is taking the collapse of the venture capital market as an opportunity to make lemonade from lemons. The effort features a distinctly Twenty First Century twist with a focus on biotech rather than silicon tech. To spearhead the effort the Boston Behemoth hired David A. Lowe as its new chief scientific officer and executive vice president for its Biosciences Group. Lowe is a former neurobiologist with the US unit of Swiss drug giant Roche Group. Mark Peterson is president of the group and Jason Rhodes a principal. Fidelity has yet to make any investments through the group.  

See the list of all the 2002 Most Influential People



Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE